Unlike the function of a preventive vaccine, the treatment targets patients infected with the virus in order to avoid their exposure to serious complications.
China, where the epidemic first appeared in Wuhan (central) at the end of 2019, was able to almost control the epidemic by adopting drastic measures such as closing borders, strict control of movement and imposing a closure.
China, which does not allow any foreign vaccine, asserts that it has vaccinated more than 70 percent of its population thanks to homemade vaccines.
Despite that, in the past months, the country faced a resurgence in confined infections, which remain less than the daily numbers announced abroad.
In a note published on Wednesday, the National Medicines Agency announced that it had given “emergency approval” for a Chinese treatment against COVID-19 based on monoclonal antibodies.
The monoclonal antibodies stick to the virus protein and reduce its ability to enter human cells.
The treatment, given by injection, was developed by the prestigious Tsinghua University in Beijing, Hospital No. 3 in Shenzhen (south), and Pre Biosciences.
Clinical trials have shown that the treatment reduces hospitalization rates and the risk of death in debilitated patients by 80 percent, according to the university.
And the local press reported that the treatment was used on patients who were infected during the renewed outbreak of the epidemic.
And on Thursday, China announced 83 new infections at the national level, as the country has several national vaccines whose effectiveness rates are lower than those manufactured abroad.
And the World Health Organization approved two vaccines from the manufacturers “Sinovac” and “Sinopharma”.
.